EP4609864A1 — Pharmaceutical composition containing isoquinolinone compound, and preparation method therefor
Assigned to Shanghai Hengrui Pharmaceutical Co Ltd · Expires 2025-09-03 · 1y expired
What this patent protects
The present disclosure relates to a pharmaceutical composition containing an isoquinolinone compound, and to a preparation method therefor. Specifically, the present disclosure provides a pharmaceutical composition containing 9,10-dimethoxy-2-[[2-(2-oxo-imidazoline-1-yl)-ethyl]-(…
USPTO Abstract
The present disclosure relates to a pharmaceutical composition containing an isoquinolinone compound, and to a preparation method therefor. Specifically, the present disclosure provides a pharmaceutical composition containing 9,10-dimethoxy-2-[[2-(2-oxo-imidazoline-1-yl)-ethyl]-(2,4,6-trimethyl-phenyl)-amino]-6,7-dihydro-pyrimidinyl[6,1-a]-isoquinolin-4-one or a pharmaceutically acceptable salt thereof, and polysorbate 80. The pharmaceutical composition of the present disclosure exhibits good physical and chemical stability after being stored for several months.
Drugs covered by this patent
- Ohtuvayre (ENSIFENTRINE) · Verona Pharma
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.